Dietrich A.  Stephan net worth and biography

Dietrich Stephan Biography and Net Worth

Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by the top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his BS from Carnegie Mellon University.

How old is Dietrich A. Stephan?

Dr. Stephan is currently 54 years old. Learn More on Dietrich A. Stephan's age.

How do I contact Dietrich A. Stephan?

The corporate mailing address for Dr. Stephan and other NeuBase Therapeutics executives is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. NeuBase Therapeutics can also be reached via phone at (164) 645-1790 and via email at [email protected]. Learn More on Dietrich A. Stephan's contact information.

Has Dietrich A. Stephan been buying or selling shares of NeuBase Therapeutics?

Dietrich A. Stephan has not been actively trading shares of NeuBase Therapeutics during the last ninety days. Most recently, on Monday, April 26th, Dietrich A. Stephan bought 600 shares of NeuBase Therapeutics stock. The stock was acquired at an average cost of $100.00 per share, with a total value of $60,000.00. Learn More on Dietrich A. Stephan's trading history.

Who are NeuBase Therapeutics' active insiders?

NeuBase Therapeutics' insider roster includes Eric Richman (Director), and Dietrich Stephan (CEO). Learn More on NeuBase Therapeutics' active insiders.

Dietrich A. Stephan Insider Trading History at NeuBase Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/26/2021Buy600$100.00$60,000.00View SEC Filing Icon  
6/9/2020Buy63$154.60$9,739.80View SEC Filing Icon  
5/21/2020Buy62$159.80$9,907.60
4/30/2020Buy500$120.00$60,000.00View SEC Filing Icon  
See Full Table

Dietrich A. Stephan Buying and Selling Activity at NeuBase Therapeutics

This chart shows Dietrich A Stephan's buying and selling at NeuBase Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NeuBase Therapeutics Company Overview

NeuBase Therapeutics logo
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $0.38
Low: $0.38
High: $0.38

50 Day Range

MA: $0.38
Low: $0.38
High: $0.38

2 Week Range

Now: $0.38
Low: $0.36
High: $4.80

Volume

N/A

Average Volume

N/A

Market Capitalization

$1.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94